Betterbrand chooses Kyowa Hakko for postbiotic ingredient in respiratory gummy supplement

Published: 25-Aug-2022

Featuring Kyowa Hakko's IMMUSE, the research-backed postbiotic provides immune support and is delivered in a simple gummy form taken daily

Betterbrand has added a new product to their respiratory and immune health supplements lineup: BetterLungs Immunity with IMMUSE.

This respiratory gummy is the first to feature IMMUSE, which was designed to support respiratory health; help reduce fatigue from exercise; provide clinically researched, year-round immune support; and help with work productivity by supporting the immune system.*

Developed by Dr Chris Jackson, Pharm.D, Betterbrand was the culmination of years of research and planning to help everyone live a better and more balanced life through natural, effective products. "Watching my grandma struggle with respiratory issues drove me to want to help the millions of others suffering with the same health issues," said Jackson. "However, in pharmacy school I realised there was an enormous opportunity to change lives through education and empowerment beyond respiratory support."

Before incorporating it into their product, Betterbrand put IMMUSE™ through a rigorous process of consideration that is standard at the company. They thoroughly researched IMMUSE, cross-referencing its claims with current scientific research to vouch for its safety, function, and potential interactions. They also ensured quality at the production source, iterated different ingredient ratios before settling on an optimal formulation, and tested their final product with a third-party lab.

"Supporting immune system health is more important than ever, and we are pleased to see our IMMUSE ingredient formulated into a Betterbrand product, knowing the care and attention paid to bringing this innovative formulation to market," commented Karen Todd, MBA, RD, Vice President Global Brand Marketing, Kyowa Hakko USA, Inc.

Each daily BetterLungs® Immunity with IMMUSE™ gummy contains 50 mg of IMMUSE LC-plasma, a postbiotic that proactively supports the immune system through a novel method of action that activates pDC (plasmacytoid dendritic cells)*. The pDC, a rare type of immune cell, has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, for a more comprehensive approach to immune support*.

IMMUSE is backed by 29 published studies, including 14 human clinical trials, and over 10 years of research. It won the 2021 Frost & Sullivan North American Immune Health Ingredient and New Product Innovation Award, and it is distributed by Kyowa Hakko, an international ingredients manufacturer whose primary goal is to provide health solutions that support optimal health for improved quality of life.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

You may also like